Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 03-18-2019, 10:09 AM #1
swept's Avatar
swept swept is offline
Junior Member
 
Join Date: Sep 2010
Location: Countryside Durham UK
Posts: 41
10 yr Member
swept swept is offline
Junior Member
swept's Avatar
 
Join Date: Sep 2010
Location: Countryside Durham UK
Posts: 41
10 yr Member
Default The alternative result GDNF

GDNF. Where now? – Jon Stamford

What should we believe?
swept is offline   Reply With QuoteReply With Quote

advertisement
Old 03-18-2019, 11:30 AM #2
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
Default

Jon's article is well worth a read. If you want to look further, it is useful to see the data in the paper [1] that includes the results for the 40 - 80 week period. The first period, 0 - 40 week, was double blinded, placebo controlled. The second period, 40 - 80 week was open label, with the original treatment group continuing as before and the original placebo group now also taking the treatment.

This GDNF trial should become a classic case study of statistical analysis. Every time a read it I come away with a different picture.

The ones that interest me today are:

LEDD mg, GDNF/GDNF, baseline= 1011, week 80= 1071
LEDD mg, Placebo/GDNF, baseline= 954, week 80= 1243

Timed tapping: OFF-state, GDNF/GDNF, baseline= 43.1, week 80= 63.8
Timed tapping: OFF-state, Placebo/GDNF, baseline= 42.4, week 80= 59.1

The increase in the levodopa equivalent daily dose especially in the Placebo/GDNF group is likely, in my opinion, to be a confounding issue.

Reference

[1] "Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease"
Alan L. Whonea et al.
Journal of Parkinson's Disease 2019, Corrected Proof
https://content.iospress.com/downloa...se%2Fjpd191576

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote
Old 03-18-2019, 12:43 PM #3
swept's Avatar
swept swept is offline
Junior Member
 
Join Date: Sep 2010
Location: Countryside Durham UK
Posts: 41
10 yr Member
swept swept is offline
Junior Member
swept's Avatar
 
Join Date: Sep 2010
Location: Countryside Durham UK
Posts: 41
10 yr Member
Default

After off meds assessment we were all given sinemet 350MG to bring us on,
Im a 5ft 2 woman what about the 15 stone 6ft man.The on dose should be titrated up to the individual need.
If I had a full English breakfast time to on was 50 minutes a banana was 10 minutes.what you eat effects outcome statistics.Im wrong perhaps but it makes sense to me it an important question
swept is offline   Reply With QuoteReply With Quote
Old 03-18-2019, 04:30 PM #4
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
Default

It makes sense to me too.

Although behind a paywall a paper by Zappia et al. [1] states:

"Patients underwent an oral acute LD test with 250 mg of LD".

"In our sample, women were significantly lighter and had a significantly greater area under the curve than men."

That suggests that women get the benefit of more levodopa.

"Moreover, a greater percentage of women showed LD peak-dose dyskinesias compared with men."

That suggests that weight has some pharmacodynamic effect.

Also, I would suggest that as the disease progresses, and dopaminergic cells die off, reducing both the endogenous production and storage of dopamine, the more closely that the pharmacodynamics follow the pharmacokinetics.

Reference:

[1] "Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease
Zappia, Mario et al.
Clinical Neuropharmacology: March-April 2002
Body Weight Influences Pharmacokinetics of Levodopa in Parki... : Clinical Neuropharmacology

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote
Reply

Tags
alternative, gdnf, result

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
EMG result help! Lindaky Spinal Disorders & Back Pain 7 05-27-2012 03:02 PM
Result!! rach73 Myasthenia Gravis 23 09-04-2009 06:29 AM
MRI result kening Spinal Disorders & Back Pain 3 06-02-2008 05:42 AM
From the author of the GDNF result paper paula_w Parkinson's Disease 25 12-02-2006 03:13 PM


All times are GMT -5. The time now is 05:45 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.